GIM
VKTX icon

Granahan Investment Management’s Viking Therapeutics VKTX Stock Holding History

Granahan Investment Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.78M Sell
148,044
-184,148
-55% -$5.95M 0.21% 109
2026
Q1 		$10.8M Buy
332,192
+96,606
+41% +$3.11M 0.52% 52
2025
Q4 		$8.29M Buy
235,586
+46,057
+24% +$1.63M 0.35% 69
2025
Q3 		$4.98M Sell
189,529
-115,562
-38% -$3.45M 0.2% 99
2025
Q2 		$8.08M Sell
305,091
-62,870
-17% -$1.66M 0.33% 75
2025
Q1 		$8.89M Buy
367,961
+62,375
+20% +$1.97M 0.44% 66
2024
Q4 		$12.3M Sell
305,586
-19,701
-6% -$1.12M 0.51% 57
2024
Q3 		$20.6M Sell
325,287
-53,411
-14% -$3.13M 0.81% 35
2024
Q2 		$20.1M Buy
378,698
+59,805
+19% +$3.92M 0.8% 37
2024
Q1 		$26.1M Buy
+318,893
New +$14.2M 0.92% 30

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Granahan Investment Management's VKTX Position: Q2 2026 in Review

Granahan Investment Management reduced its Viking Therapeutics (VKTX) stake by 55% in Q2 2026, selling an estimated $5.95M and leaving 148,044 shares worth $5.78M. The position accounts for 0.21% of the portfolio, ranked #109.

Granahan Investment Management first reported a position in VKTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $26.1M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Granahan Investment Management held 148,044 shares of Viking Therapeutics worth $5.78M as of Q2 2026.
  • Granahan Investment Management sold 184,148 Viking Therapeutics shares in Q2 2026, an estimated $5.95M.
  • Viking Therapeutics made up 0.21% of Granahan Investment Management's portfolio in Q2 2026, its #109 holding.
  • Granahan Investment Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Granahan Investment Management's Viking Therapeutics position peaked at $26.1M in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Granahan Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.